



POLYMORPHISMS OF TLR 4 AND 9 AS BIOMARKERS FOR CERVICAL DYSPLASIA AND HPV INFECTION IN A GROUP OF PUERTO RICAN WOMEN

Ana Rosario-Santos¹, MD; Magaly Martinez-Ferrer^{2,4}, Ph.D.; Alejandro O. Rivera-Torres², BS; Sofia Bravo-Torres¹, BS; Filipa Godoy-Vitorino³, Ph.D.

Josefina Romaguera-Agrait¹,MD; Keimari Mendez-Martinez, MD¹

¹University of Puerto Rico School of Medicine, Department of Obstetrics and Gynecology, ²University of Puerto Rico School of Medicine, Department of Microbiology and Medical Zoology, ⁴University of Puerto Rico School of Pharmacy, Department of Pharmaceutical Sciences

ABSTRACT	RESULTS	RESULTS
Introduction: Cervical cancer, a leading cause of mortality globally, is caused by Human Papillomavirus (HPV) in over 90% of cases. Puerto Rican women have higher incidence than other populations. Epigenetics and immune related host factors may	1 2 3 4 5 DNA Sample Collection DNA Extraction DNA Concentration DNA Detection 6 PCR DNA Concentration DNA Concentration DNA Detection PCR Detection PCR PCR PCR DNA Concentration DNA Detection DNA Detection PCR Detection PCR PCR PCR-PCR) was used to analyze SNPs for PCR TLR4 (rs4986790, rs10759931, rs11536889, rs1927911) and TLR9 (rs187084, rs5743836, rs352140, rs352140	<section-header> PCR-RFLP results of a horizontal electrophoresis.</section-header>
explain this health disparity. Toll like receptors (TLRs) are involved in the immune response of	6 7 8 9 10 Restriction Mix Electrophoresis Gel Statistical enzyme mix incubation (RFLP) Visualization Analysis (RFLP) Visualization Analysis (RFLP) Visualization Analysis	

cancer and inflammation. Single nucleotide polymorphisms(SNPs) of TLR4 and TLR9 have been related to HPV infection and cervical cancer. We aimed to correlate the presence of 8 SNPs with cervical dysplasia and HPV infection. Our hypothesis is that increased susceptibility to HPV infection and cervical dysplasia is due to these polymorphisms.

Methods:


We obtained 210 cervicovaginal samples from protocol #10510114 for our study. Information about cervical dysplasia, HPV genotype and sociodemographic data was available. We measured expression of 8 SNPs using PCR, then determined allele's frequency and analyzed its correlation with degree of cervical dysplasia and HPV positivity.

Results:

Women who expressed a NCOI of AA had 3.11 times higher odds of having dysplasia compared to women who expressed a NCOI of AG(p=0.03). Women exhibiting a CG Earl profile had 2.21 higher odds of being HPV-positive compared to women with a GG Earl. (p=0.03).

Conclusions:

We found 2 SNPs of TLR 4 to be significantly associated with severe dysplasia (NCOI) and HR-HPV infection(EARL). 35.71% of severe dysplasia patients had LR-HPV infection, raising concern for different epidemiology in PR. Future studies with other SNP's and better representation of dysplasia and cancer cases will be done to explore its use as potential biomarkers.



restriction enzymes was done in which we used: Ncol, Kpnl, Earl, Styl, AfIII, BstNl and BstUI respectively, for rs352139 an AS-PCR.

DNA Extraction from vaginal lavage and HPV genotyping.,

n= 210 cervicovaginal samples with high-resolution kit to detect 24 HR and LR HPV genotypes: 6, 11, 16, 18, 31, 33, 34, 35, 39, 40, 42, 43, 44, 45, 51, 52, 53, 54, 56, 58, 59, 66, 68/73, 70, and 74.

Age, BMI, pregnancy sociodemographic and clinical characteristics of the cases

Table 1a: Sociodemographic Characteristics	N(%) n=210	Table 1b: Clinical Characteristics
Age ¹		Dysplasia Diagnosia
Mean ± SD	39 ± 11	Yes
Median (p25 – p75)	37 (29, 48)	No
BMI Groups ¹		Dysplasia Severity
•		None
Under/Normal	64 (30.48)	Mild
Overweight	67 (31.90)	Severe
Obese	79 (37.62)	HPV Positivity ²
Pregnant ¹		Positive
Yes	43 (20.48)	(known subtypes)
No	167 (79.52)	Positive (unknown subtypes)
Drinker ¹		Negative
Yes	70 (33.33)	HPV Subtype Risk ²
	, , , , , , , , , , , , , , , , , , ,	No Risk
No	140 (66.67)	Low Risk
Smoker ¹		High Risk
Yes	19 (09.05)	Low & High Risk
Νο	191 (90.95)	Unknown Risk

Table 1b: Clinical Characteristics	N(%) n=210	
Dysplasia Diagnosis		
Yes	86 (40.95)	
Νο	124 (59.05)	
Dysplasia Severity		
None	124 (59.05)	
Mild	44 (20.95)	
Severe	42 (20.00)	
HPV Positivity ²		
Positive (known subtypes)	115 (55.56)	
Positive (unknown subtypes)	16 (07.73)	
Negative	76 (36.71)	
HPV Subtype Risk ²		
No Risk	76 (36.71)	

12 (05.80)

73 (35.27)

30 (14.49)

16 (07.73)



Figure 1. Agarose gel electrophoresis for Earl SNP rs11536889, 2.5% agarose gel in 1xTBE buffer.

PCR-RFLP results of a vertical electrophoresis.




Figure 2. Polyacrylamide gel electrophoresis for Ncol SNP rs4986790, 15% polyacrylamide gel in 1xTBE buffer.

CONCLUSIONS

- When considering dysplasia severity, our study revealed a statistically significant correlations between two polymorphisms and the disease among our sample of Puerto Rican women.
- In particular, the samples with the Ncol the (AA) genotype had 3.11 times higher odds of

INTRODUCTION

- Cervical cancer remains a leading cause of mortality among women aged 20-50 years, ranking as the fourth most common cancer in women globally despite being amenable to primary and secondary prevention strategies.
- Cervical Cancer incidence in Puerto Rico was the highest among all states of the US (12.1 per 100,000) from 2016-2020 and was the seventh most common cancer in women in Puerto Rico from 2014-2018.
- Toll-like receptors (TLRs) are part of the innate immune system as pathogen recognition receptors but are also linked to cancer biology and inflammation. TLRs are being studied for their role in HPV entry into squamous cells, especially certain SNPs of genes 4 and 9.
- The objectives of this study are to characterize TLR 4 and TLR SNP 9

Table 1. Demographic characteristics (1a) and Clinical characteristics (1b).

Ncol restriction enzyme ratios from Cervical Dysplasia on the samples.

	Un-adjusted Adjusted		sted
Dysplasia		Model 1 ²	Model 2 ³
	OR (95% CI)	OR (95% CI)	OR (95% CI)
Ncol			
AA	3.16 (1.12 - 8.89)*	3.11 (1.09 - 8.86)*	2.73 (0.94 – 7.95)
AG	REFERENCE	REFERENCE	REFERENCE
HPV Risk			
High	1.70 (0.95 - 3.03)	1.68 (0.93 - 3.01)	0.68 (0.20 – 2.32)
None/Low	REFERENCE	REFERENCE	REFERENCE

Table 2. Odds Ratios (95% Confidence Intervals)¹ for Cervical Dysplasia, according to risk factors (n=194).

LEGEND for table 2:
¹ Estimates were obtained from logistic regression models for the binary cervical dysplasia outcome (yes/no).
 ² Model 1 adjusted for age and smoking (smoker/nonsmoker). ³ Model 2 adjusted for age, smoking (smoker/nonsmoker), and HPV positivity (yes/no). * Statistically significant results p-value ≤ 0.05

Earl restriction enzyme ratios from Cervical Dysplasia on the samples.


	Un-adjusted	Adju	usted	
Positive HPV		Model 1 ²	Model 2 ³	
	OR (95% CI)	OR (95% CI)	OR (95% CI)	
Earl				
CC	3.22 (0.35 - 29.62)	3.35 (0.36 - 30.94)	3.52 (0.38 - 32.62)	
CG	2.19 (1.08 - 4.42)*	2.21 (1.09 - 4.50)*	2.19 (1.07 - 4.46)*	
GG	REFERENCE	REFERENCE	REFERENCE	

dysplasia compared to those with the (AG) allele (p=0.03).

- Despite being a polymorphism of TLR4 causing an aspartate to glycine amino acid exchange, the SNP (rs4985790) showed no statistically significant associations with cervical cancer in a study of Lithuanian patients with stage I-IV cervical cancer.
- Additionally, we found that women with a (CG) genotype in Earl profile had 2.21 times higher odds of being HPV-positive compared to those with the (GG) genotype in the Earl profile. Such polymorphisms could serve as genetic markers in diseases caused by TLR4-ligands, such as HPV infection and cervical cancer.
- Another notable observation was the detection of Low-Risk HPV in 35.71% of patients with Severe Dysplasia, raising concerns about varying HPV epidemiology in Puerto Rico.

ACKNOWLEDGEMENTS

- Hispanic Alliance for Clinical and Translational Research (Alliance)






Table 3. Odds Ratios (95% Confidence Intervals)¹ for HPV positivity, according to Earl expression (n=115).

LEGEND for table 3:
¹ Estimates were obtained from logistic regression models for the binary cervical dysplasia outcome (yes/no). ² Model 1 adjusted for age and smoking (smoker/nonsmoker).
³ Model 2 adjusted for age, smoking (smoker/nonsmoker), and severity. * Statistically significant results p-value ≤ 0.05

• The research reported was supported by the National Institute of General Medical Sciences (NIGMS) of the National Institutes of Health under award number U54GM133807. • IRB APPROVAL: IRBB3550122/ IBC # 145222 UPR Comprehensive Cancer Center facilities. Research infrastructure support and services in proteomics were provided, in part, by the grant U54MD007600 from National Institute on Minority Health and Health Disparities. Contacts: keimarimendez@gmail.com magaly.martinez1@upr.edu ana.rosario3@upr.edu

Autorizado por la Oficina del Contralor Electoral OCE-SA-2024-06118